(Q38174892)

30 August 2017

Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema (English)

1 reference

30 August 2017

0 references

1 reference

diabetic macular edema

1 reference

Ahmadreza Moradi

1

1 reference

30 August 2017

Yasir Jamal Sepah

2

1 reference

30 August 2017

Mohammad Ali Sadiq

3

1 reference

30 August 2017

Humzah Nasir

4

1 reference

30 August 2017

Salima Kherani

5

1 reference

30 August 2017

Raafay Sophie

6

1 reference

30 August 2017

Diana V Do

7

1 reference

30 August 2017

Quan Dong Nguyen

8

1 reference

30 August 2017

1 December 2013

1 reference

World journal of diabetes

30 August 2017

1 reference

30 August 2017

4

1 reference

30 August 2017

6

1 reference

30 August 2017

303-309

1 reference

Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology

30 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Current epidemiology of diabetic retinopathy and diabetic macular edema

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

The therapeutic potential of VEGF inhibition in diabetic microvascular complications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

The role of growth factors in the pathogenesis of diabetic retinopathy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Diabetic retinopathy: more than meets the eye.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

VEGF-Trap: a VEGF blocker with potent antitumor effects

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Moving toward the next steps in angiogenesis therapy?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Predicted biological activity of intravitreal VEGF Trap.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3874490

Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group

31 August 2018

1 reference

12 December 2020

Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates

1 reference

12 December 2020

Vascular endothelial growth factor Trap-Eye for diabetic macular oedema

1 reference

12 December 2020

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

Pharmacokinetics of intravitreal bevacizumab (Avastin)

1 reference

12 December 2020

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

1 reference

12 December 2020

Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration

1 reference

12 December 2020

Identifiers

DOI

10.4239/WJD.V4.I6.303

1 reference

30 August 2017

1 reference

30 August 2017

PubMed publication ID

24379921

1 reference